Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Zaremba

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 6, 2022
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaJustin Ferdinandus, Anne Zaremba, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer|May 31, 2019
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, et al.
Cancers|April 19, 2019
Frequent Occurrence of <i>NRAS</i> and <i>BRAF</i> Mutations in Human Acral NaeviPhilipp Jansen, Ioana Cosgarea, Rajmohan Murali, et al.
Pigment Cell & Melanoma Research|August 1, 2022
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsAnne Zaremba, Friedegund Meier, Christian Schlein, et al.
Frontiers in Genetics|May 27, 2021
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular TumorsPhilipp Jansen, Hansgeorg Müller, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2019
Clinical and genetic analysis of melanomas arising in acral sitesAnne Zaremba, Rajmohan Murali, Philipp Jansen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2025
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyPhilipp Jansen, Wolfgang Galetzka, Carl M Thielmann, et al.
Oncoimmunology|September 18, 2018
Evolution of melanoma cross-resistance to CD8Natalia Pieper, Anne Zaremba, Sonia Leonardelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2023
HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-ResistanceSimone Stupia, Christina Heeke, Alicia Brüggemann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2021
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalitiesEleftheria Chorti, Sied Kebir, Misbah S Ahmed, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 6, 2022
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaJustin Ferdinandus, Anne Zaremba, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer|May 31, 2019
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, et al.
Cancers|April 19, 2019
Frequent Occurrence of <i>NRAS</i> and <i>BRAF</i> Mutations in Human Acral NaeviPhilipp Jansen, Ioana Cosgarea, Rajmohan Murali, et al.
Pigment Cell & Melanoma Research|August 1, 2022
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsAnne Zaremba, Friedegund Meier, Christian Schlein, et al.
Frontiers in Genetics|May 27, 2021
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular TumorsPhilipp Jansen, Hansgeorg Müller, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2019
Clinical and genetic analysis of melanomas arising in acral sitesAnne Zaremba, Rajmohan Murali, Philipp Jansen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2025
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyPhilipp Jansen, Wolfgang Galetzka, Carl M Thielmann, et al.
Oncoimmunology|September 18, 2018
Evolution of melanoma cross-resistance to CD8Natalia Pieper, Anne Zaremba, Sonia Leonardelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2023
HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-ResistanceSimone Stupia, Christina Heeke, Alicia Brüggemann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2021
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalitiesEleftheria Chorti, Sied Kebir, Misbah S Ahmed, et al.
Pageof 5